Aptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously communicated preliminary results regarding positive safety profile for Apta-1. The GLP...
Read MoreBioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in...
Read MoreAptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management...
Read MoreBioStock published an article on 23 May 2022 about Aptahem, which can be read in full below. Aptahem has entered into an agreement with a clinical contract research organisation in the Netherlands for the implementation of the upcoming phase...
Read MoreAptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to perform the upcoming phase 1 studies with Apta-1. By entering...
Read MoreAptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och Toleranzia AB. The newly established consortium aims to evaluate new treatments to...
Read MoreBioStock published an article on 9 March 2022 about Aptahem, which can be read in full below. Aptahem has communicated several positive news lately. Recently, the company received patent protection in Japan for patent family 2 regarding the drug...
Read MoreAptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC Biotechnologies in the USA, according to timeplan. The GMP manufactured Apta-1 will be...
Read MoreAptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus challenge induced Acute Lung Injury model with Apta-1 treatment. Studies show...
Read MoreAptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application 2020-519806, the protection of the company’s drug candidate Apta-1...
Read More